Moreover, for isCGM users with suboptimal glycaemic management and baseline HbA1c ≥58.5 mmol/mol (≥7.5%), reductions in HbA1c were higher than for the overall population of isCGM users with type 2 diabetes on basal insulin or multiple daily injections (Fig. 1 and ESM Table 3). This evidence concerns the gene INS and type 2 diabetes mellitus.